Last reviewed · How we verify
MG 98
At a glance
| Generic name | MG 98 |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Daratumumab and Belatacept for Desensitization (PHASE1, PHASE2)
- Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma (PHASE2)
- Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (PHASE2)
- Oxygen Toxicity: Mechanisms in Humans (NA)
- The Effects of Subanesthetic S-ketamine on Postoperative Delirium and Cognitive Function in the Elderly Undergoing Non-cardiac Thoracic Surgery (EARLY_PHASE1)
- Modified Vaccine for High Risk or Low Residual Melanoma Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG 98 CI brief — competitive landscape report
- MG 98 updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI